• Genetic TherapyEnrolling

  Study to evaluate VX-522 in adults 18 years and older with cystic fibrosis. , protocol number Vertex VX-522-001 MAD (VX21-522-001)

  This study will evaluate the safety and tolerability of VX-522, an investigational inhaled messenger RNA (mRNA) therapy, in adults with CF whose mutations are not responsive to CFTR modulator therapy.

  • Age:

    18 Years to 65 Years

  • Mutation(s):

    No Copies F508del

  • FEV1% Predicted:

    40 to 90%

  • Number of Visits:

    33

  • Length of Participation:

    8 months

• Genetic TherapyClosed to Enrollment

  Study to evaluate VX-522 in adults 18 years and older with cystic fibrosis. , protocol number Vertex VX21-522-001 SAD

  This study will evaluate the safety and tolerability of VX-522, an investigational inhaled messenger RNA (mRNA)  therapy, in adults with CF whose mutations are not responsive to CFTR modulator therapy. 

  • Age:

    18 Years to 65 Years

  • Mutation(s):

    No Copies F508del

  • FEV1% Predicted:

    40% or greater

  • Number of Visits:

    8

  • Length of Participation:

    6 months

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.